Literature DB >> 3466738

Plasma neuropeptide Y-like immunoreactivity and catecholamines during various degrees of sympathetic activation in man.

J Pernow, J M Lundberg, L Kaijser, P Hjemdahl, E Theodorsson-Norheim, A Martinsson, B Pernow.   

Abstract

Neuropeptide Y-like immunoreactivity (NPY-LI) and catecholamine concentrations in plasma were analysed during and after 60 min of physical exercise at a work load corresponding to 70% of individual maximal oxygen uptake in nine healthy men of average physical fitness. Systemic plasma NPY-LI increased progressively from 18 +/- 3 to 81 +/- 19 pmol X 1(-1) in parallel with a 10-fold increase in noradrenaline (NA) concentration. The increase in plasma NPY-LI during exercise and the decrease after completion of exercise were much slower than the corresponding changes in NA concentration. This difference is probably related to a slower diffusion of NPY into systemic circulation after release, as well as to a longer half-life of NPY than of NA in plasma. Reversed phase HPLC and sephadex G-50 gel-filtration chromatography revealed that the main component of NPY-LI in plasma during exercise eluted in a similar position as synthetic human NPY. During exercise plasma NPY-LI correlated well with the plasma concentration of NA (r = 0.80), but not with that of adrenaline (ADR), suggesting a neuronal origin of NPY. The self-ratings of perceived exertion (RPE) were well correlated with the plasma concentrations of both NPY-LI and NA. No clear-cut veno-arterial concentration difference was observed for NPY-LI. Isometric handgrip and orthostatic test doubled plasma NA concentrations but did not cause any increase in plasma NPY-LI. No change in plasma tachykinin-like immunoreactivity was detected during exercise. The present data suggest that NPY is released together with NA during strong, but probably not during mild, sympathetic activation under physiological conditions in man.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3466738     DOI: 10.1111/j.1475-097x.1986.tb00789.x

Source DB:  PubMed          Journal:  Clin Physiol        ISSN: 0144-5979


  24 in total

1.  Impaired sympathetic vascular regulation in humans after acute dynamic exercise.

Authors:  J R Halliwill; J A Taylor; D L Eckberg
Journal:  J Physiol       Date:  1996-08-15       Impact factor: 5.182

2.  Spectral analysis of blood pressure and heart rate, catecholamine and neuropeptide Y plasma levels in a new model of neurogenic orthostatic hypotension in dog.

Authors:  P Verwaerde; J M Senard; M Mazerolles; M A Tran; C Damase-Michel; J L Montastruc; P Montastruc
Journal:  Clin Auton Res       Date:  1996-04       Impact factor: 4.435

3.  Placental Neuropeptide Y ( NPY) and NPY receptors expressions and serum NPY levels in preeclampsia.

Authors:  Roongrit Klinjampa; Chantacha Sitticharoon; Xaynaly Souvannavong-Vilivong; Chanakarn Sripong; Issarawan Keadkraichaiwat; Malika Churintaraphan; Saimai Chatree; Tripop Lertbunnaphong
Journal:  Exp Biol Med (Maywood)       Date:  2019-02-13

Review 4.  Neuroendocrine changes in chronic cardiac failure.

Authors:  D P Nicholls; G N Onuoha; G McDowell; J S Elborn; M S Riley; A M Nugent; I C Steele; C Shaw; K D Buchanan
Journal:  Basic Res Cardiol       Date:  1996       Impact factor: 17.165

5.  Morphological and molecular changes of the myocardium after left ventricular mechanical support.

Authors:  Hideo A Baba; Jeremias Wohlschlaeger
Journal:  Curr Cardiol Rev       Date:  2008-08

6.  Plasma neuropeptide Y in the symptomatic limb of patients with causalgic pain.

Authors:  P D Drummond; P M Finch; L Edvinsson; P J Goadsby
Journal:  Clin Auton Res       Date:  1994-06       Impact factor: 4.435

7.  Localization of neuropeptide Y Y1 receptors in the rat nervous system with special reference to somatic receptors on small dorsal root ganglion neurons.

Authors:  X Zhang; L Bao; Z Q Xu; J Kopp; U Arvidsson; R Elde; T Hökfelt
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-22       Impact factor: 11.205

8.  Cardiac neuropeptide Y and noradrenaline balance in patients with congestive heart failure.

Authors:  Q P Feng; T Hedner; B Andersson; J M Lundberg; F Waagstein
Journal:  Br Heart J       Date:  1994-03

9.  Neuropeptide Y levels in central and peripheral cerebrospinal fluid in patients with intracranial disorders.

Authors:  H von Holst; A Rudehill; J M Lundberg
Journal:  Acta Neurochir (Wien)       Date:  1991       Impact factor: 2.216

10.  Prevention of unfavourable effects of cigarette smoke on flap viability using botulinum toxin in random pattern flaps: An experimental study.

Authors:  Hikmet Karayel; Burak Kaya; Muzaffer Caydere; Ahmet Terzioğlu; Gürcan Aslan
Journal:  Plast Surg (Oakv)       Date:  2015       Impact factor: 0.947

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.